Phase 1 N=16 Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers
Healthy
Primary: Number of Participants With Adverse Event (AE) and Severe Adverse Event (SAE) — 0; 0; 4; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,116 Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Paroxysmal Supraventricular Tachycardia
Primary: Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting. — 324 Participants
Phase 2 N=300 A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
Coronavirus Disease-2019 (COVID-19) Prevention
Primary: Groups 1, 2, 3, 4, 5 and 6: Number of Participants With Solicited Local Adverse Events (AEs) at 7 Days Post-dose 1 — 13; 16; 17; 11 Participants
Phase 2 N=4 A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Number of Participants With Adverse Events (AEs) — 4 Participants
Phase 2 N=61 Health Evaluation in African Americans Using RAS Therapy
Alzheimer's Disease
Primary: Concentration of Angiotensin Converting Enzyme (ACE 1) — 4043.15; 4028.17; 3836.31; 3305.21 ng/mL
N/A N=146 Trial of Community Health Worker-led Decision Coaching
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Screening Rates — 77.8; 76.7 Percentage of participants
N/A N=100 reSET-O RCT (Randomized Controlled Trial)
Opioid-use Disorder
Primary: Retention in Treatment on MAT for 6 Months After Enrolling in the Study — 34; 27 Participants
Phase 3 N=458 Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
THROMBOLYSIS
Primary: Ordinal Modified Rankin Scale (mRS) Score at Day 90 — 35; 31; 38; 30 Count of participants
N/A N=55 Incline Training to Personalize Motor Control Interventions After Stroke
CVA (Cerebrovascular Accident)
Primary: Change in Gait Speed — 0.15; 0.075; 0.127 meters/second
Phase 2 N=35 A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
Primary Hyperoxaluria Type 1 (PH1) · Primary Hyperoxaluria Type 2 (PH2) · Kidney Diseases
Primary: AUC From Day 90 To Day 180, Based on Percent Change From Baseline in 24-Hour Uox — 3507.4; -1664.4 Percent change in 24-hour Uox AUC — p=<0.0001
Phase 2 N=45 HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
Diabetic Retinopathy
Primary: Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8 — 0; 0; 0 Participants
Phase 3 N=17,651 Diuretic Comparison Project
Hypertension
Primary: Time From Randomization to Composite Primary Outcome — 1.5; 1.5 Years — p=0.45
N/A N=100 Safe and Healthy Schools
Sars-CoV-2 Infection · COVID-19
Primary: Standard Diagnostic Test Outcomes for BinaxNOW at Home Testing as Compared to Nasal Swab PCR — 100; 99; 75; 100 kappa value in percentage — p=0.0015
N/A N=20 Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya
Cervical Cancer
Primary: Cervical Cancer Screening — 198; 289 individuals screened — p=<0.001
N/A N=349 WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
Atrial Fibrillation · Aortic Valve Stenosis
Primary: Composite of All-cause Mortality, Stroke and Bleeding — 60; 64 Participants